UPDATE : Monday, September 7, 2020
상단여백
HOME Pharma
Dong-A ST’s toenail fungal treatment leads local market
  • By Lee Han-soo
  • Published 2018.06.19 15:07
  • Updated 2018.06.19 18:18
  • comments 0

Dong-A ST said Jublia, the company’s toenail fungal treatment, has become a market leading product after a year of its release, the company said in a news conference Wednesday.

The prescription drug is a treatment for a nail fungal infection, also known as athlete’s foot, which causes toenails or fingernails to become thickened and discolored. The disease affects around 1.2 million people a year.

Jublia ranked first in sales in North America and Japan, too, according to 2015 IMS standards, dominating these markets after it received the go-ahead from the U.S. Food and Drug Administration in 2014. The drug received domestic approval last year.

The Ministry of Food and Drug Safety has also designated the treatment as the reference listed drug (RLD), boosting the reliability of the drug. RLD is a government-approved drug product, the new generic versions of which have to show bioequivalence to receive approval from the ministry. A drug company seeking approval to market a generic equivalent must refer to the RLD in its approval process.

During the news conference, Professor Lee Won-joo of the department of dermatology at Kyungbook National University Hospital shared a new clinical research result conducted in the U.S.

"The 52-week clinical trial confirmed that 83.8 percent of moderate to severe nail athlete's patients who used Jublia had their symptoms improved,” Professor Lee said. “The company expects that the follow-up 72-week trial will also obtain positive results.”

Lee noted that he expects Jubulia to become an effective treatment option in patients with mild to moderate-severe athlete's foot. The company is also conducting domestic phase 4 clinical trials and plans to release the results by 2020.

"The company will do its best to treat the 1.2 million toenail fungal patients easily and effectively," a company official said.

According to UBIST, a market research company, Jublia is the best-selling athlete’s foot treatment in Korea. The medication recorded the sales of 6 billion won ($5.4 million) in the first half of this year.

corea022@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Han-soo
iconMost viewed
Comments 0
More
Please leave the first comment.
여백
여백
여백
Back to Top